TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$225 Million

Generation Bio Co.

Follow-on Offering

Bookrunner, January 2021

Generation Bio Co.

Generation Bio Co. is a genetic medicines company creating a new class of gene therapy utilizing their proprietary non-viral gene therapy platform to provide durable, redosable treatments for patients living with rare and prevalent diseases. Generation Bio’s non-viral gene therapy platform incorporates the Company’s high-capacity DNA construct called closed-ended DNA, or ceDNA; their cell-targeted lipid nanoparticle delivery system, or ctLNP; and their established, scalable capsid-free manufacturing process. Using this approach, Generation Bio is developing novel gene therapies to provide targeted delivery of genetic payloads that include large and multiple genes to a range of tissues across a broad array of diseases. The Company is advancing a broad and expansive portfolio of programs including programs for rare and prevalent diseases of the liver and retina.